Trends in Renal Function among Heart-Transplant Recipients of Donor-Derived Hepatitis C Virus

Zalawadiya, Sandip; Lindenfeld, JoAnn; Shah, Ashish S.; Wigger, M.; Danter, Matthew; Brinkley, D.; Menachem, Jonathan N.; Punnoose, L.; Sacks, Suzanne Brown; Ooi, Henry; Balsara, Keki R.; Perri, Roman E.; Awad, Joseph; Smith, Sinéad M.; Fowler, R.; O’Dell, Heather; Darragh, C.; Ruzevich-Scholl, S.; Schlendorf, Kelly

doi:10.1016/j.healun.2019.01.107

Search citation statements

Order By: Relevance

Paper Sections

Select...

Hepatitis C Donors1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the rate of CAV at 1 year post-HTx was similar between recipients of HCV+ and HCV-donors (16.25% vs. 10.69%) [69]. Recipients did not develop worsened renal dysfunction either due to HCV infection or in response to treatment with sofosbuvir; an essential drug in DAA regimens [76].…”

Section: Hepatitis C Donorsmentioning

confidence: 84%

Current status and outcomes in heart transplantation: a narrative review

Awad¹,

Shah²,

Griffith³

2022

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

The first human heart transplantation was performed by Christian Barnard in 1967. While the technical aspect had been worked out, allograft rejection was a major limitation in the early days of heart transplant. The discovery of cyclosporine revolutionized the field and led to the modern era of transplant. Heart transplantation now offers the best survival benefit for patients with end-stage heart failure with a median survival over 12 years. However, there are still limitations including the impact of limited availability of graft, graft dysfunction, and rejection, and long-term non-cardiac complications. This review serves as an update on the short-and long-term outcomes following heart transplantation focusing on the new donor allocation system, efforts to expand the donor pool, primary graft dysfunction, acute cellular and antibody-mediated rejection, cardiac allograft vasculopathy, and post-transplant malignancy and renal dysfunction.

show abstract

Section: Hepatitis C Donorsmentioning

confidence: 84%